ProMIS reports PMN310 oligomer reduction at 29 days

• ProMIS reported dose-dependent reductions in detectable amyloid-beta oligomers three and 29 days after one PMN310 dose.
• No post-announcement trading was available at publication, with PMN last quoted at US$12.80 before premarket opened.
• ProMIS plans to report blinded six-month PRECISE-AD data within weeks and unblinded results in early first-quarter 2027.

ProMIS Neurosciences (NASDAQ:PMN) reported first human evidence that PMN310 reduced detectable amyloid-beta oligomers in cerebrospinal fluid dose-dependently at days three and 29, providing an exploratory signal that the antibody reached and engaged its intended target.

The new sFIDA analysis adds a pharmacodynamic measure to earlier Phase 1a findings showing dose-proportional exposure, concentrations 100–600 times estimated oligomer levels and an estimated 27-day cerebrospinal-fluid half-life.

ProMIS said PMN310 remained generally well-tolerated and strictly oligomer-selective, while the fully enrolled PRECISE-AD Phase 1b trial includes 144 participants and is expected to produce blinded six-month interim data within weeks and unblinded top-line results in early first-quarter 2027.

Following the announcement, ProMIS Neurosciences' share price was unchanged at US$12.80 before premarket trading began.

ProMIS began PRECISE-AD after completing its 40-person Phase 1a study, received FDA Fast Track designation for PMN310 in July 2025 and later enrolled 144 participants, exceeding its original 128-person target.

The company also arranged up to US$175 million in private financing in January 2026, which it said could extend its cash runway into 2028 and fund the Phase 1b programme and other clinical milestones.